Is high mobility group box 1 a novel substrate of dipeptidyl peptidase-IV?
DPP-IV cleaves HMGB1 and, via this mechanism, inhibits HMGB1 angiogenic activity. Treatment with DPP-IV inhibitors may enhance HMGB1 activity in diabetic patients, thereby improving angiogenesis in this condition.
Published literature reviews enabled physiotherapists to appraise evidence-based practices. Clinical guidelines for treating nonspecific LBP in children and adolescents are needed.